1Susan Branford Z, Rudzki A, Grigg JF, et al. BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response [ J ]. Blood, 2004, 104 : Abstract 274.
2Bengt S. Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) : update from the IRIS study [ J ]. Blood, 2005,106 : 166 - 173.
3Palandri F, Iacobucei I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML [J]. J Clin Oncol, 2008,26: 106 -111.
4Rudiger H, Ute B, Markus P, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia [ J ]. Blood ,2007,109:4686 - 4692.
5NCCN Clinical Practice Guidelines in Oncology CML V3 2008. http ://www. neen. org.
6Michele B, Giuseppe S, John G, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net [J].Blood,2006,108:1809 -1820.
7Hehlmann R, Hochhaus A, Baccarani M. European Leukemia Net. Chronic myeloid leukaemia [ J ]. Lancet, 2007,370:342 - 350.
8Robin P, Guardiola A, Devargie M, et al. A 10-year median follow- up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors [ J ]. Leukemia, 2007,19 : 1613 - 1620.
9Weisser M, Ledderose G, Jochem KH. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade [ J ]. Ann Hematol,2007 ,86 :127 - 132.
10Jerald P, Radich, Ted G, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen [ J ]. Blood, 2003,102:31 -35.
5Goldman JM, Hughes T, Radich J . Continuing reduction in level of residual disease after 4 year in patients with CML in chronic phase responding to first-line imatinib in the IRIS study. Blood, 2005,106:51a.
6Simonsson B. Beneficial ffects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) : update from the IRIS study. The IRIS study group. Blood, 2005, 106:52a.
7Savage DG, Goldman JM. Allografting for chronic myeloid leukemia. Curr Opin Hematol, 1997,4:369-376.
8Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant, 1993,12:509- 516.
9Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant, 1996,17: S5- S6.
10Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 1996, 87:2195-2204.
3Sanders JE,Im HJ,Hoffmeister PA,et al.Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.Blood,2005; 105:3749-3756.
4Peters C,Schrauder A,Schrappe M,et al.Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia:the BFM/IBFM/EBMT concepts.Bone Marrow Transplant 2005; 35 (Suppl 1):S9-11.
5Saarinen UM,Mellander L,Nysom K,et al.Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia:a retrospective case-control study in the Nordic countries.Nordic Society for Pediatric Hematology and Oncology(NOPHO).Bone Marrow Transplant.1996;17:357-363.
6Arico M,Valsecchi MG,Camitta B,et al.Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.N Engl J Med,2000;342(14):998-1006.
7Barrett AJ,HorowitzMM,Gale RP,et al.Marrow transplantation for acute lymphoblastic leukemia:factors affecting relapse and survival.Blood,1989;74(2):862-871.
8Marc Bierings,James B.Nachman C.et al.Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia:Stateof the Art and Current Challenges.Current Stem Cell Research & Therapy,2007;2,53-63.
9Alonzo TA,Wells RJ,Woods WG,et al.Postremission therapy for children with acute myeloid leukemia:the children's cancer group experience in the transplant era.Leukemia,2005;19(6):965-970.
10T Klingebiel D.Reinhardt P.Gader on behalf of the JGMT Paediatric DiseasesWorking Party,Place of HSCT in treatment of childhood AML Bone Marrow Transplantation,2008;42,S7-S9.
